Literature DB >> 33498497

Decision-making in Surgery or Active Surveillance for Low Risk Papillary Thyroid Cancer During the COVID-19 Pandemic.

Anna M Sawka1, Sangeet Ghai2, Ogemdi Ihekire3, Jennifer M Jones4, Amiram Gafni5, Nancy N Baxter6, David P Goldstein7.   

Abstract

We describe our experience conducting a prospective observational cohort study on the management of small, low risk papillary thyroid cancer during the COVID-19 pandemic. Our study participants are given the choice of active surveillance (AS) or surgery, and those in the AS arm are followed at the study center, whereas surgical patients undergo usual care. During the pandemic we have transitioned from in-person research patient visits to largely virtual care of patients under AS. As of 30 October 2020, we had enrolled 181 patients enrolled in our study (including 25 during the pandemic), of which 92.3% (167/181) consented to telephone communication and 79.0% (143/181) consented to secure videoconferencing communication. Prior to the pandemic, 74.5% (117/157) of our patients chose AS over surgery, whereas during the pandemic, 96.0% (24/25) chose AS. Of the 133 study patients who were under AS within the timeframe from 12 March 2020, to 30 October 2020, the percentage of patients who missed appointments was 8.3% (11/133, for neck ultrasound and physician visits, respectively) and delayed appointments was 23.3% (31/133). This preliminary data suggests that prospective observational research on AS of thyroid cancer can safely continue during the pandemic.

Entities:  

Keywords:  COVID-19 pandemic 3; SARS-CoV-2 4; active surveillance 2; papillary thyroid cancer 1; virtual care 5

Year:  2021        PMID: 33498497      PMCID: PMC7864172          DOI: 10.3390/cancers13030371

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  28 in total

Review 1.  Thyroid cancer in the age of COVID-19.

Authors:  Venessa H M Tsang; Matti Gild; Anthony Glover; Roderick Clifton-Bligh; Bruce G Robinson
Journal:  Endocr Relat Cancer       Date:  2020-11       Impact factor: 5.678

2.  Active surveillance in papillary thyroid carcinoma: not easily accepted but possible in Latin America.

Authors:  Anabella Smulever; Fabián Pitoia
Journal:  Arch Endocrinol Metab       Date:  2019-09-02       Impact factor: 2.309

3.  Thyroid Cancer Active Surveillance Program Retention and Adherence in Japan.

Authors:  Louise Davies; Chiang-Hua Chang; Brenda Sirovich; R Michael Tuttle; Mitsuhiro Fukushima; Yasuhiro Ito; Akira Miyauchi
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2021-01-01       Impact factor: 6.223

4.  Clearing the surgical backlog caused by COVID-19 in Ontario: a time series modelling study.

Authors:  Jonathan Wang; Saba Vahid; Maria Eberg; Shannon Milroy; John Milkovich; Frances C Wright; Amber Hunter; Ryan Kalladeen; Claudia Zanchetta; Harindra C Wijeysundera; Jonathan Irish
Journal:  CMAJ       Date:  2020-09-01       Impact factor: 8.262

5.  A Prospective Mixed-Methods Study of Decision-Making on Surgery or Active Surveillance for Low-Risk Papillary Thyroid Cancer.

Authors:  Anna M Sawka; Sangeet Ghai; Tom Yoannidis; Lorne Rotstein; Patrick J Gullane; Ralph W Gilbert; Jesse D Pasternak; Dale H Brown; Antoine Eskander; John R de Almeida; Jonathan C Irish; Kevin Higgins; Danny J Enepekides; Eric Monteiro; Avik Banerjee; Manish Shah; Everton Gooden; Afshan Zahedi; Mark Korman; Shereen Ezzat; Jennifer M Jones; Valeria E Rac; George Tomlinson; Aleksandra Stanimirovic; Amiram Gafni; Nancy N Baxter; David P Goldstein
Journal:  Thyroid       Date:  2020-04-08       Impact factor: 6.568

6.  Active Surveillance Versus Immediate Surgery: Questionnaire Survey on the Current Treatment Strategy for Adult Patients with Low-Risk Papillary Thyroid Microcarcinoma in Japan.

Authors:  Iwao Sugitani; Yasuhiro Ito; Akira Miyauchi; Tsuneo Imai; Shinichi Suzuki
Journal:  Thyroid       Date:  2019-09-25       Impact factor: 6.568

Review 7.  A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

Authors:  Humaid O Al-Shamsi; Waleed Alhazzani; Ahmad Alhuraiji; Eric A Coomes; Roy F Chemaly; Meshari Almuhanna; Robert A Wolff; Nuhad K Ibrahim; Melvin L K Chua; Sebastien J Hotte; Brandon M Meyers; Tarek Elfiki; Giuseppe Curigliano; Cathy Eng; Axel Grothey; Conghua Xie
Journal:  Oncologist       Date:  2020-04-27

8.  Teleoncology: The Youngest Pillar of Oncology.

Authors:  Puneet Pareek; Jeewan Ram Vishnoi; Sri Harsha Kombathula; Rakesh Kumar Vyas; Sanjeev Misra
Journal:  JCO Glob Oncol       Date:  2020-09

9.  Management of differentiated thyroid cancer through nuclear medicine facilities during Covid-19 emergency: the telemedicine challenge.

Authors:  Michele Klain; Carmela Nappi; Simone Maurea; Marina De Risi; Fabio Volpe; Elisa Caiazzo; Leandra Piscopo; Mariarosaria Manganelli; Martin Schlumberger; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-23       Impact factor: 9.236

10.  The reality of virtual care: Implications for cancer care beyond the pandemic.

Authors:  Danielle Rodin; Mike Lovas; Alejandro Berlin
Journal:  Healthc (Amst)       Date:  2020-10-22
View more
  3 in total

Review 1.  Mitigating the Impact of the COVID-19 Pandemic on Adult Cancer Patients through Telehealth Adoption: A Systematic Review.

Authors:  Aileen Murphy; Ann Kirby; Amy Lawlor; Frances J Drummond; Ciara Heavin
Journal:  Sensors (Basel)       Date:  2022-05-09       Impact factor: 3.847

2.  Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Zhi-Cheng Jin; Li Chen; Bin-Yan Zhong; Hai-Dong Zhu; Chu-Hui Zeng; Rui Li; Jin-He Guo; Shi-Cheng He; Gang Deng; Xiao-Li Zhu; Cai-Fang Ni; Gao-Jun Teng
Journal:  Front Oncol       Date:  2021-05-06       Impact factor: 6.244

3.  Thyroid surgery during the COVID-19 pandemic: results from a systematic review.

Authors:  L Scappaticcio; M I Maiorino; S Iorio; C Camponovo; A Piccardo; G Bellastella; G Docimo; K Esposito; P Trimboli
Journal:  J Endocrinol Invest       Date:  2021-07-19       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.